RRRonald Rodriguez

Ronald Rodriguez

*This is an algorithmically generated author record based on publicly available information.

Ronald Rodriguez has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Wasim H. Chowdhury

    Department of Urology, University of Texas Health Science Center San Antonio, San Antonio, Texas, United States of America

    6 shared publications
  • Abhinav Sidana

    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland

    5 shared publications
  • Jatinder Goyal

    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-2101, USA

    3 shared publications
  • Shawn E. Lupold

    James Buchanan Brady Urological Institute

    3 shared publications
  • Christos S. Georgiades

    Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland

    2 shared publications
  • George Netto

    Department of Pathology

    2 shared publications

Latest Publications

  • Open Access

    A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression

    by Wenjuan Cao, Junqiang Tian, Chong Li, Yanjun Gao, Xingchen Liu, Jianzhong Lu, Yuhan Wang, Zhiping Wang, Robert S. Svatek, Ronald Rodriguez

    Conditionally replicative oncolytic adenoviruses (CRAds) display significant anti-tumor effects. However, the traditional adenovirus of serotype 5 (Ad5) entering cancer cells via coxsackie virus and adenovirus receptor (CAR) can’t be utilized for bladder cancer with low expression of CAR, which limits the application of Ad5. We utilized Ad5/F11p containing the chimeric fiber gene encoding the Ad5 fiber tail domain and Ad11p fiber shaft and knob domains to construct bladder cancer-specific chimeric type viruses Ad5/F11p-PSCAE-UPII-E1A, which can infect bladder cancer cells mediated by CD46 molecule. We carried out series of experiments in vitro to research anti-tumor effect of Ad5/F11p-PSCAE-UPII-E1A and the interaction in combination with cisplatin. The results demonstrated Ad5/F11p-PSCAE-UPII-E1A could infect bladder cancer cells (T24, EJ and 5637) in a CAR-independent way, and exert anti-tumor effect by blocking the cancer cells in G1 phase and inducing apoptosis. Ad5/F11p-PSCAE-UPII-E1A plus cisplatin enhanced the anti-proliferative effect and increased the number of apoptotic cells compared with viruses or cisplatin alone. Ad5/F11p-PSCAE-UPII-E1A plus cisplatin could upregulate the proteins expression of p53, Bax, and cleaved caspase-3, and downregulated Bcl-2 protein expression in T24, EJ and 5637 cells. We constructed a bladder cancer-specific oncolytic adenovirus and provided new combination treatment strategies for bladder cancer.


  • Single-Center Comparative Oncologic Outcomes of Surgical and Percutaneous Cryoablation for Treatment of Renal Tumors

    by Jatinder Goyal, Payal Verma, Abhinav Sidana, Christos S. Georgiades, Ronald Rodriguez

    Purpose: To compare outcomes between patients undergoing surgical and percutaneous cryoablation for treatment of renal masses and identify prognostic variables that determine survival. Patients and Methods: We retrospectively evaluated the medical records of 194 patients who underwent cryoablation for renal tumors between 1997 and 2008 at a single large center. Patient demographics, tumor characteristics, perioperative data, and follow-up details were recorded. Univariate and multivariate Cox proportional hazards analysis was performed to identify predictors of overall (OS), cancer-specific (CSS), and recurrence-free survival (RFS). Results: Cryoablation was performed percutaneously (PCA) in 141 patients for 154 tumors, while 53 patients were treated surgically (SCA) using an open or laparoscopic approach for 54 tumors. Mean follow-up was 44.5 months in SCA and 36.1 months in PCA. PCA had a shorter duration of hospital stay (0.7 days vs 3.2 days, PP=0.38) and recurrent disease (P=0.18) was not significantly different between the two groups. Five-year OS, CSS, and RFS were 78.81%, 100%, and 85.23% for SCA, and 77.71%, 98%, and 95.56% for PCA, respectively; the type of approach was not predictive of OS, CSS, and RFS. Conclusions: SCA and PCA both provide adequate oncologic control for renal masses. Duration of hospital stay was lower in patients undergoing PCA.


  • Determinants of outcomes after resection of renal cell carcinoma with venous involvement

    by Abhinav Sidana, Jatinder Goyal, Piyush Aggarwal, Payal Verma, Ronald Rodriguez

    Purpose To determine the outcomes and to identify prognostic variables determining mortality and recurrence after surgery for renal cell cancer (RCC) with venous involvement. Methods Retrospective evaluation of the medical records of 132 patients with RCC and tumor thrombi treated at Johns Hopkins Hospital (1997–2008) was done. Kaplan–Meier analysis was used to determine survivals. Uni- and multivariate Cox proportional analysis was done to identify predictors for recurrence, all-cause mortality (ACM) and cancer-specific mortality (CSM). Results Mean follow-up was 30.3 (0.03–159.5) months. Sixty-four (48.5 %) patients had renal vein thrombus (Group 1), 55 (41.7 %) had subdiaphragmatic inferior vena cava (IVC) tumor thrombus (Group 2), while 13 (9.8 %) had involvement of IVC above diaphragm or atrial extension (Group 3). IVC thrombus was more common from the right-sided tumors. Patients with higher thrombus levels had more blood loss and complicated and longer hospital stay. Thrombus level was not found to be a predictor of recurrence, ACM and CSM. One- and three-year recurrence-free survivals for non-metastatic patients were 69 and 53 %. Tumor size (p = 0.015), grade (p = 0.007) and venous wall invasion (p = 0.027) were predictors for recurrence. Five-year overall survival was 48, 35 and 13 % for 3 groups, respectively. Presence of distant metastasis (p = 0.032), size (p = 0.002), histology (p = 0.020) and grade (p = 0.013) were predictors of ACM. Five-year cancer-specific survival was 65, 43 and 36 for 3 groups, respectively. Tumor size (p = 0.001) and distant metastasis at presentation (p = 0.025) were the predictors of CSM. Conclusions Tumor thrombus level does not predict recurrence or mortality in RCC with venous involvement. Survival is determined by inherent aggressiveness of the cancer manifested by tumor size, grade and distant metastasis at presentation.


  • Open Access

    Mechanism of Growth Inhibition of Prostate Cancer Xenografts by Valproic Acid

    by Abhinav Sidana, Muwen Wang, Shabana Shabbeer, Wasim H. Chowdhury, George Netto, Shawn E. Lupold, Michael Carducci, Ronald Rodriguez

    Valproic Acid (VPA), a histone deacetylase inhibitor, has been demonstrated to cause a marked decrease in proliferation of prostate cancer (PCa) cellsin vitroand a significant reduction in tumor volumein vivo. The goal of this study is to better understand the VPA-induced growth inhibitionin vivo, by studying expression of various markers in PCa xenografts.Methods. Forin vitroexperiments, PCa cells were treated with 0, 0.6, and 1.2 mM VPA for 14 days. Forin vivomodels, experimental animals received 0.4% VPA in drinking water for 35 days. Tissue microarray was generated using cell pellets and excised xenografts.Results. VPA treatment causes cell cycle arrest in PCa cellsin vivo, as determined by increase in p21 and p27 and decrease in cyclin D1 expression. Increased expression of cytokeratin18 was also seen in xenografts. LNCaP xenografts in treated animals had reduced androgen receptor (AR) expression. While decreased proliferation was foundin vitro, increase in apoptosis was found to be the reason for decreased tumor growthin vivo. Also, an anti-angiogenic effect was observed after VPA treatment.Conclusion. VPA inhibits tumor growth by multiple mechanisms including cell cycle arrest, induction of differentiation, and inhibition of growth of tumor vasculature.


  • Open Access

    A Real Time Metridia Luciferase Based Non-Invasive Reporter Assay of Mammalian Cell Viability and Cytotoxicity via the β-actin Promoter and Enhancer

    by Shawn E. Lupold, Tamara Johnson, Wasim H. Chowdhury, Ronald Rodriguez

    Secreted reporter molecules offer a means to evaluate biological processes in real time without the need to sacrifice samples at pre-determined endpoints. Here we have adapted the secreted bioluminescent reporter gene, Metridia luciferase, for use in a real-time viability assay for mammalian cells. The coding region of the marine copepod gene has been codon optimized for expression in human cells (hMLuc) and placed under the control of the human β-actin promoter and enhancer. Metridia luciferase activity of stably transfected cell models corresponded linearly with cell number over a 4-log dynamic range, detecting as few as 40 cells. When compared to standard endpoint viability assays, which measure the mitochondrial dehydrogenase reduction of tetrazolium salts, the hMLuc viability assay had a broader linear range of detection, was applicable to large tissue culture vessels, and allowed the same sample to be repeatedly measured over several days. Additional studies confirmed that MLuc activity was inhibited by serum, but demonstrated that assay activity remained linear and was measurable in the serum of mice bearing subcutaneous hMLuc-expressing tumors. In summary, these comparative studies demonstrate the value of humanized Metridia luciferase as an inexpensive and non-invasive method for analyzing viable cell number, growth, tumor volume, and therapeutic response in real time.


  • Open Access

    Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer

    by Z Zhai, Z Wang, S Fu, J Lu, F Wang, R Li, H Zhang, S Li, Z Hou, H Wang, et al.

    The high frequency of recurrence and poor survival rate of bladder cancer demand exploration of novel strategies. Gene therapy via adenovirus has shown promising potential for the treatment of tumors. We constructed a bladder cancer-specific adenovirus carrying E1A-androgen receptor (AR) under the control of UPII promoter and prostate stem cell antigen enhancer (PSCAE), designated as Ad/PSCAE/UPII/E1A-AR, and investigated its antitumor effects in vitro and in vivo. We demonstrated that Ad/PSCAE/UPII/E1A-AR could be selectively replicated in bladder tumor cell lines (5637, BIU87, EJ and T24) when compared with control adenovirus Ad/PSCAE/UPII/Luc. However, there was no evidence of cytotoxicity for normal human bladder cell line SV-HUC-1 and hepatoma cell line SMMC7721. AR agonist R1881 could strengthen the oncolytic effect of Ad/PSCAE/UPII/E1A-AR in bladder cancer cells. In addition, we demonstrated that intratumoral injection of Ad/PSCAE/UPII/E1A-AR into established subcutaneous human EJ tumors in nude mice could significantly regress the growth of tumor and markedly prolong survival for tumor-bearing mice; on the other hand, saline-treated tumors continued to grow rapidly. Our studies indicate that Ad/PSCAE/UPII/E1A-AR could effectively treat bladder cancer in vitro and in vivo. Furthermore, our findings provide a promising therapeutic modality for the treatment of bladder cancer.


  • Open Access

    Renal Function and Oncologic Outcomes after Cryoablation or Partial Nephrectomy for Tumors in Solitary Kidneys

    by Jatinder Goyal, Abhinav Sidana, Christos S. Georgiades, Ronald Rodriguez

    Goyal J, et al. Korean J Urol. 2011 Jun;52(6):384-389. http://dx.doi.org/10.4111/kju.2011.52.6.384


  • Adenovirus Targeting to Prostate-Specific Membrane Antigen through Virus-Displayed, Semirandom Peptide Library Screening

    by Ping Wu, Tarana A. Kudrolli, Wasim H. Chowdhury, Minzhi M. Liu, Ronald Rodriguez, Shawn E. Lupold

    The convergence of phage-displayed peptide libraries and recombinant viral vectors launched a promising new direction in targeted viral gene therapeutics, but the translation of targeting peptides to functional cancer therapeutic agents has been challenging. Here, we report progress in developing a successful strategy to optimize targeted viral infection through adenovirus-displayed, semirandom peptide libraries. A phage-derived peptide targeting the prostate-specific membrane antigen (PSMA) was genetically incorporated into the adenoviral capsid Fiber protein and flanked by random peptide cassettes. The resulting adenovirus library was biopanned against PSMA-expressing cells and tumors to identify a PSMA-retargeted adenovirus. While the initial peptide alone could not target viral infection, the selected virus preferentially infects PSMA-expressing cells through the targeting peptide and infects LNCaP tumors after intravenous injection. Our results indicate that virus-displayed, semirandom peptide libraries can be used to optimize targeting infection. This approach represents a novel principle for developing targeted agents in a variety of disease models. Cancer Res; 70(23); 9549–53. ©2010 AACR.


  • Open Access

    Does Valproic Acid Induce Neuroendocrine Differentiation in Prostate Cancer?

    by Abhinav Sidana, Muwen Wang, Wasim H. Chowdhury, Antoun Toubaji, Shabana Shabbeer, George Netto, Michael Carducci, Shawn E. Lupold, Ronald Rodriguez

    Valproic Acid (VPA) is a histone deacetylase inhibitor that holds promise for cancer therapy. Here, we investigate whether VPA treatment induces neuroendocrine differentiation of Prostate Cancer (PCa). A tissue microarray of VPA‐treated and untreated tumor xenografts and cell lines of human PCa (LNCaP, C4‐2, DU145, and PC‐3) were generated and were analyzed by immunohistochemical analysis (IHC) for NE markers chromogranin A (CgA), synaptophysin, and NCAM (neural cell adhesion molecule). Western blot analysis for CgA was performed to confirm the results of the TMA. IHC analysis did not reveal any induction of CgA, synaptophysin, or NCAM in any xenograft after VPA treatment in vivo. In vitro, VPA treatment induced little synaptophysin expression in C4‐2 and PC‐3 cells and NCAM expression in LNCaP and PC‐3 cells. In the case of CgA, VPA treatment decreased its expression in vitro in a dose‐dependent manner, as determined by western blot analysis. Thus our data demonstrates that VPA does not induce NE differentiation of PCa cells in the physiologically relevant in vivo setting.


  • Open Access

    Androgen Receptor Attenuation of Ad5 Replication: Implications for the Development of Conditionally Replication Competent Adenoviruses

    by Naseruddin Höti, Ying Li, Chien-Lun Chen, Wasim H Chowdhury, David C Johns, Qinghua Xia, Arup Kabul, Jer-Tsong Hsieh, Michael Berg, Gary Ketner, et al.